Results Case Studies

Please click on the tabs below to read case studies that illustrate examples of significant outcomes from previous Pacific Health Summits.

Click to expand Case Study

2012 - World Vision, DSM, & Myanmar Ministry of Health: Bringing Nutrition Technologies to Rice Millers

The 2012 Summit galvanized collaboration in nutrition innovations in Asia. A Summit dinner targeting key stakeholders from selected countries in Asia, including Vietnam, Myanmar, and Japan, resulted in a partnership between Ministry of Health staff in Myanmar with World Vision and DSM to see how NutriRice innovation can be implemented in Myanmar in the context of small-scale rice millers.

Utilizing affordable technologies, the project will enhance the nutritional status of children, adolescent girls, pregnant and lactating mothers. In the wake of the collaboration, Stefan Germann, Director, Learning & Partnerships, Global Health and HIV Team, World Vision International, noted that “The ability of the Pacific Health Summit to bring together the private sector, foundations, government, and non-profit stakeholders, creates a unique opportunity for such convergence to address critical issues that matter. Key is good pre-summit preparation and timely follow-up after the summit."

2011 - GE Healthcare and M+W Group: Alliance to Bolster Emerging Nation Vaccine Production

Reflecting on his experience at the 2011 Summit, Dr. Nigel Darby, Vice President, BioTechnologies & Chief Technology Officer, GE Healthcare Life Sciences, wrote: “In the specific area of vaccine production, there was a clear undercurrent amongst the discussions that the status quo cannot continue. The change being requested is for localized manufacturing, so that more vaccines are produced in the areas where they are needed.”

The thinking behind these sentiments ultimately resulted in a new business strategy for GE Healthcare. Recognizing the opportunities the Summit presents, Dr. Darby began to meet with senior representatives from leading manufacturing companies, governments and other key stakeholders to explain where GE Healthcare could partner to further the goal of self-sufficient vaccine manufacturing within countries. In early December, an official announcement that GE Healthcare would form a strategic alliance with M+W Group, a global leader in engineering and construction for technology projects, affirmed that the change being requested had become the change being made.

Together, GE Healthcare and M+W Group will offer governments and pharmaceutical companies a streamlined, cost-effective and turn-key approach to the creation of new biopharmaceutical manufacturing plants. In emerging nations around the world, the plants will represent a significant step toward building the in-country capacity that is necessary to locally produce vaccines, insulin, and other biopharmaceuticals for populations in need.

David Boyd, Director of European Government & Public Policy, GE Healthcare, who also participated in the Summit, noted: “Our public commitment to this began with Nigel Darby’s expert interview in advance of the 2011 Pacific Health Summit, and participation in a panel at the Summit where he called for action to be taken to change the way the world manufactures vaccines. I’m delighted to see real action result.”

2011 - The Coca-Cola Company: Engaging Partners for Health

Every year, a series of private dinners hosted by Summit partners helps further the Summit’s mission to provide impetus for collaboration. Some of the most vibrant outcomes from past Summits, including the Critical Path to TB Drug Regimens, have resulted from conversations during private dinners. At the 2011 Summit, The Coca-Cola Company (TCCC) brought together an international caucus of representatives from government, civil society, and academia.

The assemblage represented an exciting opportunity to engage key opinion leaders about the health issues that matter most to them, and to learn how and where TCCC can help drive solutions. “It was important for us to hear what these leaders think about our Company and what we should be doing to address many of the health challenges impacting our world,” explains Rhona Applebaum, Chief Scientific and Regulatory Officer.

Dr. Applebaum and Guy Wollaert, Senior Vice President and Chief Technology Officer, heard an array of opinions, ranging from environmental concerns, to immunization and challenges in global health. Aligned with the Summit’s goal of driving change through conversation and dialogue, the quorum’s feedback will assist in contributing to TCCC’s “health and well-being" paradigm, and discourse surrounding its future endeavors.

2011 - Merck and Serum Institute of India: Pneumococcal Conjugate Vaccine

On August 3, 2011, key Summit leaders from Merck and the Serum Institute of India Ltd. (SIIL) announced they would work in concert to develop and commercialize a 15-valent pneumococcal conjugate vaccine (PCV) for use in emerging economies and the developing world.

This collaborative-development partnership combines know-how and technology,” stated Mark Feinberg, Vice President & Chief Public Health and Science Officer, Merck Vaccines, Merck & Co. “We need to develop solutions that go beyond traditional structures, models, and pathways. While the initial discussions of this collaboration began before the Summit, the value of innovative approaches that bring together new partners who share a common commitment to advancing global health progress was confirmed by the discussions at the Summit.”

A common cause of meningitis and pneumonia, pneumococcal disease is fatal to over one million children every year. Suresh Jadhav, Executive Director, SIIL, confirmed that the new vaccine will be manufactured at the Institute's plant in Pune, India, and that it will be made available to UN agencies at an affordable price. The partnership leverages common resources and goals to achieve both companies' ultimate aim of bringing new vaccines to the developing world.

2011 - A Model of Trust: Center for Public Decisionmaking Surrounding Immunization

Vaccines are perhaps the most cost-effective and efficacious intervention in the global health arsenal, but without parents’, and the overall public’s, trust in vaccines’ ability to safely prevent disease, much of their life-saving power can be lost.

The 2011 Summit furthered a powerful model for building trust and public confidence in vaccines. The initiative was catalyzed by a first-time meeting between Heidi Larson, Senior Lecturer, Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, and Michael Watson, Vice President, Global Immunization Policy, sanofi pasteur, at the 2010 Summit. Joining forces, they began to formalize a center for public decisionmaking around immunization. Together, they officially launched The Vaccine Confidence Network in 2012. Housed at the London School of Hygiene & Tropical Medicine, the project deploys a multidisciplinary network of researchers to develop and pursue a collaborative research agenda to better understand and tackle issues around public confidence in, and acceptance of, vaccines.

2011 - Swedish, PNRI, and GE: Mobile Technology for Addressing Type 2 Diabetes

The 2011 Pacific Health Summit provided an opportune setting for Swedish Medical Center and the Pacific Northwest Diabetes Research Institute (PNRI) to assemble a targeted working group of Summit participants from across sectors to discuss how mobile technology can help predict, prevent, and manage type 2 diabetes in underserved communities.

The two organizations issued a Call for Collaboration that is linked to their Global to Local project, which targets communities near Seattle, Washington that have a health status comparable to many developing world populations. Recognizing that the plethora of research, technology, and low-cost health strategies intended for global populations has equal potential in the Seattle community, the project draws a global health arsenal to bear on pressing local health needs.

“Our working session identified a number of key issues and principles associated with the potential for improving the effectiveness and efficiency of diabetes prevention and treatment using mobile technology, social media, and related strategies,” noted Dr. Jack Faris, CEO, PNRI. As a direct result of the session, GE came on board as the technology partner for the Global to Local initiative. GE is committed to defining and providing mobile health-oriented technology that the initiative can deploy in the field.

Further outcomes from the meeting are emerging. A database is being built to catalog the working group’s input, and to create a resource in which to archive projects, research, and other relevant information pertaining to the use of mobile technology to combat diabetes. Additionally, a framework for ongoing collaboration ensures that the unique nature of the group can continue to be leveraged as the project advances.

2010 - Laerdal and Jhpiego: Helping Mother's Deliver

In 2010, the Summit’s steady emphasis on connecting unlike minds again proved fruitful as two complementary partners, Jhpiego and Laerdal, found common ground in Helping Mothers Deliver. The project is a joint effort to sharply reduce deaths resulting from post partum hemorrhage, the malignant cause of over 120,000 maternal deaths a year.

In meetings at the Summit, Jhpiego and Laerdal conceptualized a plan that would allow them to team up to create an impactful line of instructive birth resources. The resulting Helping Mother’s Deliver course follows the model of Laerdal’s Helping Babies Breathe. The program is replete with action plans, clinical reminders, learner workbooks, and flip chart illustrations that provide guidance in low-resource settings where instruction may be otherwise unavailable. Headlining Laerdal’s innovative tutorial tools is MamaNatalie, an award-winning birthing simulator that helps train for complex birthing scenarios, including excessive bleeding. Jhpiego is currently utilizing its existing networks in Tanzania, Ethiopia, and India to conduct field tests and prepare MamaNatalie for the course.

2010 - Laerdal and Powerfree Education and Technology: Launching Products into Production

The Pacific Health Summit’s commitment to helping cross-sector players form new partnerships is embodied each year in its “Calls for Collaboration.” The Calls allow organizations to highlight areas in which they are looking to partner around a specific challenge or health theme. In 2010, Powerfree Education and Technology’s PET) Call resulted in a striking contribution to MNH, and efforts to meet MDGs 4 and 5.

PET’s emphasis on developing low-cost, energy independent devices had led to the creation of innovative pulse oximeters and Freeplay Energy’s fetal heart rate monitors, each with the potential to transform MNH care in low resource settings. Nearing the devices’ manufacturing stage, PET needed a partner to help refine the current versions of the products, assist in their distribution, and develop instructions to improve the quality of care when using the devices.

Amongst Summit participants, PET found a fitting partner in Laerdal. Famous for creating and producing the now ubiquitous CPR training manikin, Laerdal specializes in instructional courses and simulation tools that augment the skills of health workers. Laerdal has also been successfully involved in myriad product launches. It leveraged its expertise to help arrange the manufacture and production of both devices.

2010 - Mobile Alliance for Maternal Action (MAMA)

Conversations at the 2010 Summit on Maternal and Newborn Health sparked interest about the potential of mobile phones to deliver critical health messages to mothers in resource-limited settings, helping catalyze events which would lead to the establishment of the Mobile Alliance for Maternal Action (MAMA). “The excitement at the Pacific Health Summit around the concept of using mobile phones to reach women in resource-low settings with critical health information about pregnancy and the first year of life generated momentum within Johnson & Johnson and BabyCenter to make this component a key part of our commitment to the UN Secretary General’s Global Strategy for Women and Children’s Health,” said Tina Sharkey, Chairman & Global President, BabyCenter.

One year after this embryonic beginning, the sentiments generated by the Summit found tangible application in MAMA. An invaluable partnership among founding partners Johnson & Johnson, U.S. Agency for International Development (USAID), with support from mHealth Alliance, UN Foundation, and BabyCenter, a subsidiary of Johnson & Johnson, MAMA is committed to improving maternal and child health by empowering mothers through health messages that are delivered through texts or voice-automated calls. The messages are tailored to a mother’s pregnancy stage or her newborn child’s age, providing time-sensitive information at the moments when mothers need it most.

Representing the Summit ideal of collaboration, MAMA is a vivacious model of how to synchronize the abilities of distinctive sectors into a complementary partnership. Development of the mobile content is being led by BabyCenter, the internet’s foremost parenting network. In-country partners will localize the content based on cultural, social, and health paradigms, and disseminate in local languages. The mHealth Alliance will foster global connections and collaboration among a broad community engaged in mobile health work through knowledge-sharing and capacity building activities.

Johnson & Johnson and USAID act as strategic advisors and provide funding, encouraging the creation of effective, scalable and sustainable programs. MAMA will initially operate in Bangladesh, India, and South Africa, and aims to advance the field globally in order to reach mothers throughout the world.

2009 - Critical Path to TB Drug Regimens

In early 2009, the outline of a potentially landmark public-private partnership to streamline Tuberculosis drug development had begun to emerge. The Critical Path to TB Drug Regimens (CPTR), as it would come to be known, held standalone promise as overdue relief to the stymied TB drug pipeline. Its efforts to streamline the development, testing, regulatory science, and manufacturing of TB drugs were envisioned to effectively reduce drug development time by 75%, cutting the timeline from nearly a quarter of a century, to only six years.

To work, the partnership required specific buy-in from partners across sectors. By convening elite leaders in TB across every field, the 2009 Pacific Health Summit on MDR-TB played an integral role in moving the framework of CPTR forward. The Summit presented a timely opportunity to engage possible partners in an in-person conversation. Recognizing the opportunity, a private dinner was organized to host potential CPTR partners, and to help cement links and agreements with industry that would be imperative to the collaboration’s overall success.

With added impetus from the Summit dinner, the CPTR formally launched on March 18, 2010. Founding partners the Critical Path Institute, TB Alliance, and Bill & Melinda Gates Foundation were joined in an historic partnership by industry organizations. These included 2009 Summit participants: AstraZeneca, Bayer, GlaxoSmithKline, Johnson & Johnson, Otsuka, Pfizer, and Sanofi Aventis. Another Summit partner, the non-profit Treatment Action Group (TAG), also joined.

Together, these companies will share information, develop fresh funding, promote new regulatory approaches, and work cohesively to test TB drug candidates early in the development process. Testing new drugs in combination, rather than in an ossified one-by-one approach, and without recourse to which company is sponsoring or manufacturing the drug, has the benefit of significantly reducing the time that it will take for the most effective TB drugs to enter use. In working with academia and regulators, CPTR’s mission also includes breaking down policy barriers that have contributed to the TB drug development quagmire, to more quickly help those most in need.

By uniting all sectors behind a common interest for the sake of a common good, the CPTR is an exemplar of the Summit’s profound belief in the power of action. Its collaboration stands a potential model to accelerate and streamline efficiency across drug pipelines in a range of diseases.

2009 - Merck and Qiagen: Cervical Cancer Screening and Vaccination

Some of the most influential global partnerships begin through informal conversations at the Pacific Health Summit each year. During the 2009 Summit, Mark Feinberg, Vice President, Medical Affairs and Policy, Merck, and Qiagen CEO, Peer Schatz, conceptualized a remarkable joint venture, pairing their companies’ respective vaccines and diagnostics capabilities in a coordinated fight against the spread of cervical cancer.

Merck pledged 5 million free doses of its Gardasil HPV vaccine, and Qiagen heightened its existing test donation program by providing free digene HC2 HPV DNA and careHPV tests to an additional 500,000 women in resource poor areas. The collaboration was particularly notable for being the first time that a vaccines manufacturer and a molecular diagnostics company had united in such a manner.

Since the 2009 Summit, the collaboration has amplified. Additional vaccine donations to protect 12-15 year-old girls in Rwanda and free screenings for women aged 35-45 were announced in 2011. Future plans include expansion of the program to several other African countries. Each year, the Summit’s intent is to create a milieu which fosters dialogue between like-minded leaders; the burgeoning reach of the Merck and Qiagen partnership is a testament to the influence that a conversation may have on global health.

2008 - Access to Nutrition Index

“How Can We Put Business to Work to Address the Global Nutrition Challenge?” More than just the title of a plenary session at the 2008 Pacific Health Summit on nutrition, the question of how to best utilize business’ creativity became the central theme of that year’s Summit discussions. Recognizing that industry could be a prime driver in alleviating the cost of both malnutrition and obesity, Mark Walport, CEO, Wellcome Trust, and Tachi Yamada, then-president, Bill & Melinda Gates Foundation, converted words into action, conceptualizing what would become the groundbreaking Access to Nutrition Index (ATNI). The Global Alliance for Improved Nutrition’s (GAIN) Chairman, Jay Naidoo, and Executive Director, Marc Van Ameringen—both Summit 2008 participants—committed GAIN as the implementing partner for the project.

The ATNI will rate the top 25 food companies in the world based on their strategies and policies on nutrition, and their effectiveness in producing affordable, healthy products. Three sub-indexes will rank the top ten food companies in India, South Africa, and Mexico.

By pitting their creative, competitive energies against each other, the Index will create an environment which stimulates companies to continue to improve existing practices, and gives them a way to measure results. Additionally, the rankings create tangible benchmarks that can be used by investors, policymakers, and consumers, to make informed decisions, building a feedback loop which rewards good practice.

Together three Summit partners have designed the Access to Nutrition Index to resourcefully leverage industry’s unparalleled influence, resources, and drive to address problems underpinning global nutrition.

2007 - Flu Vaccine Donations and Global Stockpile

In the midst of mounting concern about the threat of an avian flu pandemic, and reservations about abilities to manufacture and distribute the necessary volume of vaccines, the 2007 Summit on pandemics commenced at a uniquely pressing time in global health.

Against this backdrop, in an address to the Pacific Health Summit, Director-General of the World Health Organization (WHO), Margaret Chan, made a historic announcement detailing the WHO’s commitment to creating a global avian influenza stockpile.

“In April, a strategic advisory group of experts confirmed the scientific feasibility of establishing an H5N1 vaccine stockpile…WHO has initiated work to establish such a stockpile,” she stated.

A simultaneous announcement was made at the Summit that GlaxoSmithKline Biologicals had pledged a donation of 50 million doses of pre-pandemic influenza vaccine to help establish the vaccine supply. Other industry partners, including Sanofi Pasteur, Omnivest, and Baxter, joined in making similar donations to augment vaccine reserves.

Two years later, in recognition of the spirit of collaboration engendered by the Summit, Chris Viehbacher, CEO, Sanofi, chose the 2009 Summit as the forum to announce that Sanofi would add an additional 100 million doses of swine flu vaccine to the WHO stockpile. The contribution was essential to help ensure that people living in developing countries would have the same access to vaccines as those in developed countries.

2007 - Hilleman Laboratories

Wellcome Trust Chairman Sir William Castell’s conversation with Mark Feinberg, Vice President, Medical Affairs and Health Policy, Merck, at the 2007 Pacific Health Summit resulted in the realization of both organizations’ complimentary vision to increase access to lifesaving vaccines in developing countries. Launched by the Wellcome Trust and MSD (known in the United States and Canada as Merck) in September 2009, and based in New Dehli, India, the MSD Wellcome Trust Hilleman Laboratories marks the first time a research philanthropy and a pharmaceutical company have partnered to form a separate entity with equally-shared funding and decision-making rights. Hilleman’s not-for-profit mission focuses on developing affordable vaccines that meet the needs of developing countries.

In January 2011, Hilleman Laboratories announced its first project: a feasibility study of how new technologies might be used to develop a rotavirus vaccine designed specifically for developing country needs, partnering with the non-profit MEND, whose CEO participated in the 2009 Summit.

Novel technologies the Hilleman Laboratories is examining include formulations based on dissolving thin strips for their potential to improve thermostability, ease of use, transportation, and affordability. If the initial study is successful, it will explore options to further develop the technology for rotavirus and other oral vaccines of importance to developing country health.

Back to Top